{"success":true,"data":{"pressRelease":{"id":"32305","rtpr_id":"nGNX2n6dn5","ticker":"IBIO","exchange":"NASDAQ","all_tickers":["IBIO"],"title":"iBio Reports Q3 Fiscal Year 2026 Financial Results and Provides Corporate Update","author":"Globe Newswire","published_at":"2026-05-12T20:05:02.346Z","article_body":"Received regulatory clearance to initiate its Phase 1 clinical trial of\nIBIO-600 in Australia\n\nAnnounced a strategic pipeline expansion into pulmonary hypertension\nassociated with heart failure with preserved ejection fraction (PH-HFpEF) of\nits bispecific antibody \n\nReported new preclinical data from its obese non-human primate (NHP) study\nevaluating IBIO-610, with visceral fat reduced by 6.7% and total fat mass by\n5.2% \n\nSAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- iBio, Inc.\n(https://www.globenewswire.com/Tracker?data=PfV2q_AORn_jHx3DhJbI4qYAO9C5Mc0XolszM3DnJKLhVL09KXsuKlG2W3k7y2XqfIgTXBEBjXPHQ1QOSBMhew==)\n(NASDAQ:IBIO), an AI-driven innovator developing therapies for\ncardiometabolic, obesity and cardiopulmonary diseases, today reported\nfinancial results for the third quarter ended Mar. 31, 2026, and provided a\ncorporate update on its progress.\n\n“This last quarter was marked by significant advancement across our full\npipeline. Most importantly, we received the clearance to enter the clinic with\nIBIO-600, which we believe has best-in-class potential due to its ability to\npreserve lean mass and improve body composition in obesity,” said Martin\nBrenner, D.V.M., Ph.D., Chief Executive Officer and Chief Scientific Officer\nof iBio. “We also presented new data for IBIO-610 demonstrating targeted\nreduction of total and visceral fat in obese non-human primates (NHPs) and\nexpanded our pipeline with our selective bispecific antibody designed to block\nActivin A, GDF8 (myostatin) and GDF11, potentially to treat PH-HFpEF, which\nrepresents a high unmet need. Together, these milestones continue to\ndemonstrate the significant potential of our platform and our commitment to\ndeveloping differentiated therapies to meaningfully impact the lives of\npatients.”\n\nThird Fiscal Quarter 2026 & Recent Corporate Updates:\n* Announced receipt\n(https://ir.ibioinc.com/news-events/press-releases/detail/257/ibio-received-regulatory-clearance-to-initiate-its-phase-1-clinical-trial-of-ibio-600-in-australiahttps:/ir.ibioinc.com/news-events/press-releases/detail/257/ibio-received-regulatory-clearance-to-initiate-its-phase-1-clinical-trial-of-ibio-600-in-australia)\nof Clinical Trial Notification (CTN) acknowledgement from Australia’s\nTherapeutic Goods Administration (TGA) and Human Research Ethics Committee\n(HREC) approval to initiate a first-in-human Phase 1 clinical trial of\nIBIO-600, a long-acting anti-myostatin monoclonal antibody designed to\npreserve lean mass and improve body composition. The randomized, double-blind,\nplacebo-controlled, single ascending dose study will evaluate safety,\ntolerability, pharmacokinetics, and pharmacodynamics of IBIO-600 in overweight\nand obese adults, with first participant dosing expected in the second quarter\nof calendar 2026. \n* Announced a strategic pipeline expansion\n(https://ir.ibioinc.com/news-events/press-releases/detail/256/ibio-to-provide-an-update-on-cardiopulmonary-program-targeting-pulmonary-hypertension-associated-with-heart-failure-with-preserved-ejection-fraction-ph-hfpef)\ninto pulmonary hypertension associated with heart failure with preserved\nejection fraction (PH-HFpEF). iBio is engineering a selective bispecific\nantibody designed to block Activin A, GDF8 (myostatin), and GDF11 to reduce\ncardiac fibrosis, reverse pulmonary vascular remodeling, and improve whole\nbody functional capacity, while avoiding safety issues linked to broader TGFβ\nligand blockade. \n* Presented new preclinical data\n(https://ir.ibioinc.com/news-events/press-releases/detail/255/ibio-reports-preclinical-body-composition-data-from-obese-non-human-primates-treated-with-ibio-610-a-potential-first-in-class-treatment-for-fat-selective-weight-loss) from its\nobese non-human primate (NHP) study evaluating IBIO-610, potentially a\nfirst-in-class Activin E antibody candidate. The preclinical body composition\ndata demonstrate IBIO-610 reduced fat mass in obese NHPs compared to\nvehicle-treated obese NHPs, in a small, not statistically powered study.\nFollowing two once-every-eight-week dosing, IBIO-610 reduced visceral fat by\n6.7% and total fat mass by 5.2%, with only a slight increase in lean mass\nfollowing treatment.\n* Delivered an oral presentation at Drug R&D on February 24, 2026, titled\n“Accelerating Antibody Drug Discovery with Artificial Intelligence.”\n* Delivered a company presentation at Biocom California's Global Life Science\nPartnering & Investor Conference on February 25, 2026.\n* Participated in fireside chats at the Leerink Global Healthcare Conference\nand the Oppenheimer 36(th) Annual Healthcare Life Sciences Conference.\nFinancial Results:\n\nNo revenue was recognized for the three months ended March 31, 2026 and 2025.\n\nResearch and Development (“R&D”) expenses for the three months ended March\n31, 2026, and March 31, 2025, were $3.3 million and $1.9 million,\nrespectively, an increase of approximately $1.4 million. The increase in R&D\nexpenses is primarily due to increased spending for consultants and outside\nservices supporting the Company’s R&D efforts, including conducting the NHP\nstudies and CMC activities, and an increase in personnel costs as a result of\nadvancing research activities for the Company’s IBIO-600 and IBIO-610\nprograms and other preclinical pipeline assets.\n\nGeneral and Administrative expenses for the three months ending March 31,\n2026, and March 31, 2025, were approximately $5.1 million and $3 million,\nrespectively, an increase of $2.1 million. The increase is primarily\nattributable to the impairment of the Company’s indefinite-lived intangible\nasset IBIO-101 of $2.5 million offset by lower IT related costs and franchise\ntaxes.\n\niBio held cash, cash equivalents and investments in debt securities of $74.8\nmillion as of March 31, 2026. In addition, in the fourth quarter of fiscal\nyear 2026, the Company received gross proceeds of approximately $17 million\nfrom warrant exercises extending the Company’s cash runway into fourth\nquarter of fiscal year 2028.\n\nAbout iBio, Inc.\n\niBio (Nasdaq: IBIO) is a cutting-edge biotech company leveraging AI and\nadvanced computational biology to develop next-generation biopharmaceuticals\nfor cardiometabolic and cardiopulmonary diseases, obesity, cancer and other\nhard-to-treat diseases. By combining proprietary 3D modeling with innovative\ndrug discovery platforms, iBio is creating a pipeline of breakthrough antibody\ntreatments to address significant unmet medical needs. iBio’s mission is to\ntransform drug discovery, accelerate development timelines, and unlock new\npossibilities in precision medicine. For more information,\nvisit www.ibioinc.com or follow iBio on LinkedIn\n(https://www.globenewswire.com/Tracker?data=iQn28ljOPQedqVELZ9qGagH-WoCO0fhJr8IGE-Q9iFWERjHaGSudbPuT5z85FjNsUz2xC6-7f44ZjgbnmSBGcUs3q375D8R6tCa3q9XrYE58bCOtRCpo8sNKOpKvY_jc).\n\nFORWARD-LOOKING STATEMENTS\n\nCertain statements in this press release constitute \"forward-looking\nstatements\" within the meaning of the federal securities laws. Words such as\n\"may,\" \"might,\" \"will,\" \"should,\" \"believe,\" \"expect,\" \"anticipate,\"\n\"estimate,\" \"continue,\" \"predict,\" \"forecast,\" \"project,\" \"plan,\" \"intend\" or\nsimilar expressions, or statements regarding intent, belief, or current\nexpectations, are forward-looking statements. These forward-looking statements\nare based upon current estimates and assumptions and include statements\nregarding the potential of IBIO-600 to be best-in-class; IBIO-600’s ability\nto preserve lean mass and improve body composition in obesity; the significant\npotential of the Company’s platform and its commitment to developing\ndifferentiated therapies to meaningfully impact the lives of patients;\ninitiation of a first-in-human Phase 1 clinical trial of IBIO-600, the\npotential of IBIO-600 to be a best-in-class, long-acting anti-myostatin\nmonoclonal antibody; evaluation of the safety, tolerability, pharmacokinetics,\nand pharmacodynamics of IBIO-600 in overweight and obese adults in a\nrandomized, double-blind, placebo-controlled, single ascending dose study; the\ndosing of the first participant in the IBIO-600 Phase 1 clinical trial in the\nsecond quarter of calendar 2026; iBio’s engineering of a selective\nbispecific antibody designed to block Activin A, GDF8 (myostatin), and GDF11;\nthe selective bispecific antibody reducing cardiac fibrosis, reversing\npulmonary vascular remodeling, and improving whole body functional capacity,\nwhile avoiding safety issues linked to broader TGFβ ligand blockade; the\npotential of IBIO-610 to be a first-in-class Activin E antibody candidate; the\nnet proceeds of the warrant exercises in the fourth quarter of fiscal year\n2026 extending the Company’s cash runway into fourth quarter of fiscal year\n2028; the Company’s ability to leverage AI and advanced computational\nbiology to develop next-generation biopharmaceuticals for cardiometabolic and\ncardiopulmonary diseases, obesity, cancer and other hard-to-treat diseases;\niBio’s ability to combine its proprietary 3D modeling with its innovative\ndrug discovery platforms to create a pipeline of breakthrough antibody\ntreatments to address significant unmet medical needs; and iBio’s ability to\ntransform drug discovery, accelerate development timelines, and unlock new\npossibilities in precision medicine. While iBio believes these forward-looking\nstatements are reasonable, undue reliance should not be placed on any such\nforward-looking statements, which are based on information available to us on\nthe date of this release. These forward-looking statements are subject to\nvarious risks and uncertainties, many of which are difficult to predict that\ncould cause actual results to differ materially from current expectations and\nassumptions from those set forth or implied by any forward-looking statements.\nImportant factors that could cause actual results to differ materially from\ncurrent expectations include, among others, the ability of iBio to initiate a\nfirst-in-human Phase 1 clinical trial of IBIO-600, with the dosing of the\nfirst participant in the IBIO-600 Phase 1 clinical trial in the second quarter\nof calendar 2026; iBio’s ability to obtain regulatory approvals for\ncommercialization of its product candidates, or to comply with ongoing\nregulatory requirements; regulatory limitations relating to iBio’s ability\nto promote or commercialize its product candidates for specific indications;\nacceptance of iBio’s product candidates in the marketplace and the\nsuccessful development, marketing or sale of products; and whether iBio will\nincur unforeseen expenses or liabilities or other market factors; and the\nother factors discussed in iBio’s filings with the SEC including its Annual\nReport on Form 10-K for the year ended June 30, 2025 and its subsequent\nfilings with the SEC on Forms 10-Q and 8-K. The information in this release is\nprovided only as of the date of this release, and iBio undertakes no\nobligation to update any forward-looking statements contained in this release\non account of new information, future events, or otherwise, except as required\nby law.\n\nContact:\n\niBio, Inc. \nInvestor Relations \nir@ibioinc.com \n\nIgnacio Guerrero-Ros, Ph.D., or David Schull\nRusso Partners, LLC\nIgnacio.guerrero-ros@russopartnersllc.com\n\n(https://www.globenewswire.com/Tracker?data=8uSp-3F3pQZpmtgALgHlKrhr5vZjAj_qhC8kev1dn0lskqaeixuyrsQvFxvhq2Yy8LXNPobrmxnlDez5X3njbxLqkBAEJe103jolbFeU5DBCVQqW33z1tbpE_UwXvYYaVSD8Y7VNTOhQeBI6aV9r7qwHse-KDPFdDWwpMBiNzCZISprHRUlUV9ua-xHj2VBIw2WJW7aMxuyMXtObA0evK7SF89FAclPfk6L1BOg9zCK12Wu1_91lyqJWfgO5P0OpqRdpTAR4MKlhvY3Gi_cq4j1S_bZGBR1SKAnFKIsZnaWYfYfq6s9FLeuuTx_gtb0w7ziMnm37YDH8xJVBom8qvA==)David.schull@russopartnersllc.com\n\n(https://www.globenewswire.com/Tracker?data=hZ7TI7mpm4jGuHds1jLau8cwRxo8_FcTnz9U3TwbH8L9mtaYvAki5Rh1HnvztJ6Eh-bu7W7upZAU1UfXE_J3oNS7Wzk0rf4sUgrCNEat4VfUBSAkxIhxCCCUP4YEV7b8rn9A_U9hM-yqEuSQLiE6FvKryFovCPJv91mr-8nfMuOyX3YKBCiCl_QLhsTsgL3J8kN9bM3RlTLMK8TSH1nzvtsh-2fuPIFfi561fvpED6yD4Ri73d9aaAbI0UWHks3E1uC1XuKBhyKj3J5D9wucWrMb9fL3Zhq7KMPkDfBQ3Ug=)(858)\n717-2310 or (646) 942-5604\n\n iBio, Inc. and Subsidiaries Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited; in thousands, except per share amounts) \n \n Three Months Ended Nine Months Ended \n March 31, March 31, \n 2026 2025 2026 2025 \n \n Revenue $ — $ — $ 100 $ 200 \n \n Operating expenses: \n Research and development 3,254 1,906 11,084 5,088 \n General and administrative 5,111 2,973 12,777 8,516 \n Total operating expenses 8,365 4,879 23,861 13,604 \n \n Operating loss (8,365 ) (4,879 ) (23,761 ) (13,404 ) \n \n Other income (expense): \n Interest income 657 72 1,417 358 \n Interest expense (22 ) (54 ) (99 ) (168 ) \n Total other income (expense) 635 18 1,318 190 \n \n Net loss $ (7,730 ) $ (4,861 ) $ (22,443 ) $ (13,214 ) \n \n Comprehensive loss: \n Net loss $ (7,730 ) $ (4,861 ) $ (22,443 ) $ (13,214 ) \n Other comprehensive loss - unrealized loss on on debt securities (32 ) — (21 ) — \n \n Comprehensive loss $ (7,762 ) $ (4,861 ) $ (22,464 ) $ (13,214 ) \n \n Loss per common share - basic and diluted $ (0.07 ) $ (0.49 ) $ (0.26 ) $ (1.44 ) \n \n Weighted-average common shares outstanding - basic and diluted - see Note 16 117,470 9,862 86,048 9,202 \n\n\n\n iBio, Inc. and Subsidiaries Condensed Consolidated Balance Sheets (In thousands, except share and per share amounts) \n \n \n March31, June30, \n 2026 2025 \n (Unaudited) \n Assets \n Current assets: \n Cash and cash equivalents $ 47,631 $ 8,582 \n Accounts receivable - trade, net of allowance for credit losses of $65 and $0 as of March 31, 2026 and June 30, 2025, respectively — — \n Investments in debt securities (adjusted cost $27,156 and $0, respectively - see Note 6) 27,166 — \n Subscription receivable — 105 \n Prepaid expenses and other current assets 2,454 1,034 \n Total Current Assets 77,251 9,721 \n \n Restricted cash 228 210 \n Promissory note receivable 1,157 1,098 \n Finance lease right-of-use assets, net of accumulated amortization — 68 \n Operating lease right-of-use asset 1,766 2,051 \n Fixed assets, net of accumulated depreciation 3,310 3,163 \n Intangible assets, net of accumulated amortization 1,830 6,848 \n Prepaid expenses - noncurrent 282 — \n Security deposits 10 26 \n Total Assets $ 85,834 $ 23,185 \n \n Liabilities and Stockholders' Equity \n Current liabilities: \n Accounts payable $ 3,035 $ 2,188 \n Accrued expenses 1,787 1,345 \n Finance lease obligations — 53 \n Operating lease obligation - current portion 532 490 \n Equipment financing payable - current portion — 64 \n Term promissory note — 766 \n Contract liabilities 1,150 1,200 \n Total Current Liabilities 6,504 6,106 \n \n Operating lease obligation - net of current portion 1,793 2,199 \n Total Liabilities 8,297 8,305 \n \n Stockholders' Equity \n Preferred Stock - $0.001 par value; 1,000,000 shares authorized; 0 shares issued and outstanding (see Note 15 - Stockholders' Equity) — — \n Common Stock - $0.001 par value; 275,000,000 shares authorized; 34,543,561 and 19,349,201 shares issued and outstanding as of March 31, 2026 and June 30, 2025, respectively 35 19 \n Additional paid-in capital 432,190 347,085 \n Accumulated other comprehensive loss (21 ) — \n Accumulated deficit (354,667 ) (332,224 ) \n Total Stockholders’ Equity 77,537 14,880 \n Total Liabilities and Stockholders' Equity $ 85,834 $ 23,185 \n\n\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/c472b1f4-0d21-4a83-b703-3214f1faebbc)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX2n6dn5","title":"iBio Reports Q3 Fiscal Year 2026 Financial Results and Provides Corporate Update","author":"Globe Newswire","ticker":"IBIO","created":"2026-05-12T20:05:02.346Z","tickers":["IBIO"],"exchange":"NASDAQ","article_body":"Received regulatory clearance to initiate its Phase 1 clinical trial of\nIBIO-600 in Australia\n\nAnnounced a strategic pipeline expansion into pulmonary hypertension\nassociated with heart failure with preserved ejection fraction (PH-HFpEF) of\nits bispecific antibody \n\nReported new preclinical data from its obese non-human primate (NHP) study\nevaluating IBIO-610, with visceral fat reduced by 6.7% and total fat mass by\n5.2% \n\nSAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- iBio, Inc.\n(https://www.globenewswire.com/Tracker?data=PfV2q_AORn_jHx3DhJbI4qYAO9C5Mc0XolszM3DnJKLhVL09KXsuKlG2W3k7y2XqfIgTXBEBjXPHQ1QOSBMhew==)\n(NASDAQ:IBIO), an AI-driven innovator developing therapies for\ncardiometabolic, obesity and cardiopulmonary diseases, today reported\nfinancial results for the third quarter ended Mar. 31, 2026, and provided a\ncorporate update on its progress.\n\n“This last quarter was marked by significant advancement across our full\npipeline. Most importantly, we received the clearance to enter the clinic with\nIBIO-600, which we believe has best-in-class potential due to its ability to\npreserve lean mass and improve body composition in obesity,” said Martin\nBrenner, D.V.M., Ph.D., Chief Executive Officer and Chief Scientific Officer\nof iBio. “We also presented new data for IBIO-610 demonstrating targeted\nreduction of total and visceral fat in obese non-human primates (NHPs) and\nexpanded our pipeline with our selective bispecific antibody designed to block\nActivin A, GDF8 (myostatin) and GDF11, potentially to treat PH-HFpEF, which\nrepresents a high unmet need. Together, these milestones continue to\ndemonstrate the significant potential of our platform and our commitment to\ndeveloping differentiated therapies to meaningfully impact the lives of\npatients.”\n\nThird Fiscal Quarter 2026 & Recent Corporate Updates:\n* Announced receipt\n(https://ir.ibioinc.com/news-events/press-releases/detail/257/ibio-received-regulatory-clearance-to-initiate-its-phase-1-clinical-trial-of-ibio-600-in-australiahttps:/ir.ibioinc.com/news-events/press-releases/detail/257/ibio-received-regulatory-clearance-to-initiate-its-phase-1-clinical-trial-of-ibio-600-in-australia)\nof Clinical Trial Notification (CTN) acknowledgement from Australia’s\nTherapeutic Goods Administration (TGA) and Human Research Ethics Committee\n(HREC) approval to initiate a first-in-human Phase 1 clinical trial of\nIBIO-600, a long-acting anti-myostatin monoclonal antibody designed to\npreserve lean mass and improve body composition. The randomized, double-blind,\nplacebo-controlled, single ascending dose study will evaluate safety,\ntolerability, pharmacokinetics, and pharmacodynamics of IBIO-600 in overweight\nand obese adults, with first participant dosing expected in the second quarter\nof calendar 2026. \n* Announced a strategic pipeline expansion\n(https://ir.ibioinc.com/news-events/press-releases/detail/256/ibio-to-provide-an-update-on-cardiopulmonary-program-targeting-pulmonary-hypertension-associated-with-heart-failure-with-preserved-ejection-fraction-ph-hfpef)\ninto pulmonary hypertension associated with heart failure with preserved\nejection fraction (PH-HFpEF). iBio is engineering a selective bispecific\nantibody designed to block Activin A, GDF8 (myostatin), and GDF11 to reduce\ncardiac fibrosis, reverse pulmonary vascular remodeling, and improve whole\nbody functional capacity, while avoiding safety issues linked to broader TGFβ\nligand blockade. \n* Presented new preclinical data\n(https://ir.ibioinc.com/news-events/press-releases/detail/255/ibio-reports-preclinical-body-composition-data-from-obese-non-human-primates-treated-with-ibio-610-a-potential-first-in-class-treatment-for-fat-selective-weight-loss) from its\nobese non-human primate (NHP) study evaluating IBIO-610, potentially a\nfirst-in-class Activin E antibody candidate. The preclinical body composition\ndata demonstrate IBIO-610 reduced fat mass in obese NHPs compared to\nvehicle-treated obese NHPs, in a small, not statistically powered study.\nFollowing two once-every-eight-week dosing, IBIO-610 reduced visceral fat by\n6.7% and total fat mass by 5.2%, with only a slight increase in lean mass\nfollowing treatment.\n* Delivered an oral presentation at Drug R&D on February 24, 2026, titled\n“Accelerating Antibody Drug Discovery with Artificial Intelligence.”\n* Delivered a company presentation at Biocom California's Global Life Science\nPartnering & Investor Conference on February 25, 2026.\n* Participated in fireside chats at the Leerink Global Healthcare Conference\nand the Oppenheimer 36(th) Annual Healthcare Life Sciences Conference.\nFinancial Results:\n\nNo revenue was recognized for the three months ended March 31, 2026 and 2025.\n\nResearch and Development (“R&D”) expenses for the three months ended March\n31, 2026, and March 31, 2025, were $3.3 million and $1.9 million,\nrespectively, an increase of approximately $1.4 million. The increase in R&D\nexpenses is primarily due to increased spending for consultants and outside\nservices supporting the Company’s R&D efforts, including conducting the NHP\nstudies and CMC activities, and an increase in personnel costs as a result of\nadvancing research activities for the Company’s IBIO-600 and IBIO-610\nprograms and other preclinical pipeline assets.\n\nGeneral and Administrative expenses for the three months ending March 31,\n2026, and March 31, 2025, were approximately $5.1 million and $3 million,\nrespectively, an increase of $2.1 million. The increase is primarily\nattributable to the impairment of the Company’s indefinite-lived intangible\nasset IBIO-101 of $2.5 million offset by lower IT related costs and franchise\ntaxes.\n\niBio held cash, cash equivalents and investments in debt securities of $74.8\nmillion as of March 31, 2026. In addition, in the fourth quarter of fiscal\nyear 2026, the Company received gross proceeds of approximately $17 million\nfrom warrant exercises extending the Company’s cash runway into fourth\nquarter of fiscal year 2028.\n\nAbout iBio, Inc.\n\niBio (Nasdaq: IBIO) is a cutting-edge biotech company leveraging AI and\nadvanced computational biology to develop next-generation biopharmaceuticals\nfor cardiometabolic and cardiopulmonary diseases, obesity, cancer and other\nhard-to-treat diseases. By combining proprietary 3D modeling with innovative\ndrug discovery platforms, iBio is creating a pipeline of breakthrough antibody\ntreatments to address significant unmet medical needs. iBio’s mission is to\ntransform drug discovery, accelerate development timelines, and unlock new\npossibilities in precision medicine. For more information,\nvisit www.ibioinc.com or follow iBio on LinkedIn\n(https://www.globenewswire.com/Tracker?data=iQn28ljOPQedqVELZ9qGagH-WoCO0fhJr8IGE-Q9iFWERjHaGSudbPuT5z85FjNsUz2xC6-7f44ZjgbnmSBGcUs3q375D8R6tCa3q9XrYE58bCOtRCpo8sNKOpKvY_jc).\n\nFORWARD-LOOKING STATEMENTS\n\nCertain statements in this press release constitute \"forward-looking\nstatements\" within the meaning of the federal securities laws. Words such as\n\"may,\" \"might,\" \"will,\" \"should,\" \"believe,\" \"expect,\" \"anticipate,\"\n\"estimate,\" \"continue,\" \"predict,\" \"forecast,\" \"project,\" \"plan,\" \"intend\" or\nsimilar expressions, or statements regarding intent, belief, or current\nexpectations, are forward-looking statements. These forward-looking statements\nare based upon current estimates and assumptions and include statements\nregarding the potential of IBIO-600 to be best-in-class; IBIO-600’s ability\nto preserve lean mass and improve body composition in obesity; the significant\npotential of the Company’s platform and its commitment to developing\ndifferentiated therapies to meaningfully impact the lives of patients;\ninitiation of a first-in-human Phase 1 clinical trial of IBIO-600, the\npotential of IBIO-600 to be a best-in-class, long-acting anti-myostatin\nmonoclonal antibody; evaluation of the safety, tolerability, pharmacokinetics,\nand pharmacodynamics of IBIO-600 in overweight and obese adults in a\nrandomized, double-blind, placebo-controlled, single ascending dose study; the\ndosing of the first participant in the IBIO-600 Phase 1 clinical trial in the\nsecond quarter of calendar 2026; iBio’s engineering of a selective\nbispecific antibody designed to block Activin A, GDF8 (myostatin), and GDF11;\nthe selective bispecific antibody reducing cardiac fibrosis, reversing\npulmonary vascular remodeling, and improving whole body functional capacity,\nwhile avoiding safety issues linked to broader TGFβ ligand blockade; the\npotential of IBIO-610 to be a first-in-class Activin E antibody candidate; the\nnet proceeds of the warrant exercises in the fourth quarter of fiscal year\n2026 extending the Company’s cash runway into fourth quarter of fiscal year\n2028; the Company’s ability to leverage AI and advanced computational\nbiology to develop next-generation biopharmaceuticals for cardiometabolic and\ncardiopulmonary diseases, obesity, cancer and other hard-to-treat diseases;\niBio’s ability to combine its proprietary 3D modeling with its innovative\ndrug discovery platforms to create a pipeline of breakthrough antibody\ntreatments to address significant unmet medical needs; and iBio’s ability to\ntransform drug discovery, accelerate development timelines, and unlock new\npossibilities in precision medicine. While iBio believes these forward-looking\nstatements are reasonable, undue reliance should not be placed on any such\nforward-looking statements, which are based on information available to us on\nthe date of this release. These forward-looking statements are subject to\nvarious risks and uncertainties, many of which are difficult to predict that\ncould cause actual results to differ materially from current expectations and\nassumptions from those set forth or implied by any forward-looking statements.\nImportant factors that could cause actual results to differ materially from\ncurrent expectations include, among others, the ability of iBio to initiate a\nfirst-in-human Phase 1 clinical trial of IBIO-600, with the dosing of the\nfirst participant in the IBIO-600 Phase 1 clinical trial in the second quarter\nof calendar 2026; iBio’s ability to obtain regulatory approvals for\ncommercialization of its product candidates, or to comply with ongoing\nregulatory requirements; regulatory limitations relating to iBio’s ability\nto promote or commercialize its product candidates for specific indications;\nacceptance of iBio’s product candidates in the marketplace and the\nsuccessful development, marketing or sale of products; and whether iBio will\nincur unforeseen expenses or liabilities or other market factors; and the\nother factors discussed in iBio’s filings with the SEC including its Annual\nReport on Form 10-K for the year ended June 30, 2025 and its subsequent\nfilings with the SEC on Forms 10-Q and 8-K. The information in this release is\nprovided only as of the date of this release, and iBio undertakes no\nobligation to update any forward-looking statements contained in this release\non account of new information, future events, or otherwise, except as required\nby law.\n\nContact:\n\niBio, Inc. \nInvestor Relations \nir@ibioinc.com \n\nIgnacio Guerrero-Ros, Ph.D., or David Schull\nRusso Partners, LLC\nIgnacio.guerrero-ros@russopartnersllc.com\n\n(https://www.globenewswire.com/Tracker?data=8uSp-3F3pQZpmtgALgHlKrhr5vZjAj_qhC8kev1dn0lskqaeixuyrsQvFxvhq2Yy8LXNPobrmxnlDez5X3njbxLqkBAEJe103jolbFeU5DBCVQqW33z1tbpE_UwXvYYaVSD8Y7VNTOhQeBI6aV9r7qwHse-KDPFdDWwpMBiNzCZISprHRUlUV9ua-xHj2VBIw2WJW7aMxuyMXtObA0evK7SF89FAclPfk6L1BOg9zCK12Wu1_91lyqJWfgO5P0OpqRdpTAR4MKlhvY3Gi_cq4j1S_bZGBR1SKAnFKIsZnaWYfYfq6s9FLeuuTx_gtb0w7ziMnm37YDH8xJVBom8qvA==)David.schull@russopartnersllc.com\n\n(https://www.globenewswire.com/Tracker?data=hZ7TI7mpm4jGuHds1jLau8cwRxo8_FcTnz9U3TwbH8L9mtaYvAki5Rh1HnvztJ6Eh-bu7W7upZAU1UfXE_J3oNS7Wzk0rf4sUgrCNEat4VfUBSAkxIhxCCCUP4YEV7b8rn9A_U9hM-yqEuSQLiE6FvKryFovCPJv91mr-8nfMuOyX3YKBCiCl_QLhsTsgL3J8kN9bM3RlTLMK8TSH1nzvtsh-2fuPIFfi561fvpED6yD4Ri73d9aaAbI0UWHks3E1uC1XuKBhyKj3J5D9wucWrMb9fL3Zhq7KMPkDfBQ3Ug=)(858)\n717-2310 or (646) 942-5604\n\n iBio, Inc. and Subsidiaries Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited; in thousands, except per share amounts) \n \n Three Months Ended Nine Months Ended \n March 31, March 31, \n 2026 2025 2026 2025 \n \n Revenue $ — $ — $ 100 $ 200 \n \n Operating expenses: \n Research and development 3,254 1,906 11,084 5,088 \n General and administrative 5,111 2,973 12,777 8,516 \n Total operating expenses 8,365 4,879 23,861 13,604 \n \n Operating loss (8,365 ) (4,879 ) (23,761 ) (13,404 ) \n \n Other income (expense): \n Interest income 657 72 1,417 358 \n Interest expense (22 ) (54 ) (99 ) (168 ) \n Total other income (expense) 635 18 1,318 190 \n \n Net loss $ (7,730 ) $ (4,861 ) $ (22,443 ) $ (13,214 ) \n \n Comprehensive loss: \n Net loss $ (7,730 ) $ (4,861 ) $ (22,443 ) $ (13,214 ) \n Other comprehensive loss - unrealized loss on on debt securities (32 ) — (21 ) — \n \n Comprehensive loss $ (7,762 ) $ (4,861 ) $ (22,464 ) $ (13,214 ) \n \n Loss per common share - basic and diluted $ (0.07 ) $ (0.49 ) $ (0.26 ) $ (1.44 ) \n \n Weighted-average common shares outstanding - basic and diluted - see Note 16 117,470 9,862 86,048 9,202 \n\n\n\n iBio, Inc. and Subsidiaries Condensed Consolidated Balance Sheets (In thousands, except share and per share amounts) \n \n \n March31, June30, \n 2026 2025 \n (Unaudited) \n Assets \n Current assets: \n Cash and cash equivalents $ 47,631 $ 8,582 \n Accounts receivable - trade, net of allowance for credit losses of $65 and $0 as of March 31, 2026 and June 30, 2025, respectively — — \n Investments in debt securities (adjusted cost $27,156 and $0, respectively - see Note 6) 27,166 — \n Subscription receivable — 105 \n Prepaid expenses and other current assets 2,454 1,034 \n Total Current Assets 77,251 9,721 \n \n Restricted cash 228 210 \n Promissory note receivable 1,157 1,098 \n Finance lease right-of-use assets, net of accumulated amortization — 68 \n Operating lease right-of-use asset 1,766 2,051 \n Fixed assets, net of accumulated depreciation 3,310 3,163 \n Intangible assets, net of accumulated amortization 1,830 6,848 \n Prepaid expenses - noncurrent 282 — \n Security deposits 10 26 \n Total Assets $ 85,834 $ 23,185 \n \n Liabilities and Stockholders' Equity \n Current liabilities: \n Accounts payable $ 3,035 $ 2,188 \n Accrued expenses 1,787 1,345 \n Finance lease obligations — 53 \n Operating lease obligation - current portion 532 490 \n Equipment financing payable - current portion — 64 \n Term promissory note — 766 \n Contract liabilities 1,150 1,200 \n Total Current Liabilities 6,504 6,106 \n \n Operating lease obligation - net of current portion 1,793 2,199 \n Total Liabilities 8,297 8,305 \n \n Stockholders' Equity \n Preferred Stock - $0.001 par value; 1,000,000 shares authorized; 0 shares issued and outstanding (see Note 15 - Stockholders' Equity) — — \n Common Stock - $0.001 par value; 275,000,000 shares authorized; 34,543,561 and 19,349,201 shares issued and outstanding as of March 31, 2026 and June 30, 2025, respectively 35 19 \n Additional paid-in capital 432,190 347,085 \n Accumulated other comprehensive loss (21 ) — \n Accumulated deficit (354,667 ) (332,224 ) \n Total Stockholders’ Equity 77,537 14,880 \n Total Liabilities and Stockholders' Equity $ 85,834 $ 23,185 \n\n\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/c472b1f4-0d21-4a83-b703-3214f1faebbc)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-05-12T20:05:02.405324331Z","server_sent_at_ms":1778616302405},"received_at":"2026-05-12T20:05:02.679Z","source_url":null},"analysis":null,"durationMs":null,"modelName":null}}